ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
Jubilant Ingrevia has issued Commercial Papers worth Rs. 100 Crore. This issuance, with a 90-day tenure, falls within the previously approved Rs. 600 Crore outstanding limit.
Jubilant Ingrevia Employees Welfare Trust sold 8,807 shares worth Rs.0.56 Crore. The sale was executed to facilitate the exercise of ESOP options.
Jubilant Ingrevia Employees Welfare Trust sold 2,587 equity shares worth Rs. 0.17 Crore on September 11, 2026.
Jubilant Ingrevia Employees Welfare Trust sold 5,622 equity shares for Rs. 0.38 Crore. The transfer was executed pursuant to the exercise of ESOPs.
Jubilant Ingrevia reported a strong Q1 FY27 with revenue at a 15-quarter high of INR 1,300 Cr (up 25% YoY). Strategy focuses on the 'Pinnacle' journey, expanding CDMO and Specialty Chemical pipelines.
Jubilant Ingrevia Ltd reported revenue from operations of ₹1,300 Cr (+25.2% YoY) and net profit of ₹106 Cr (+41.3% YoY) for Q1 FY27.
Jubilant Ingrevia Ltd reported revenue from operations of ₹1,300 Cr (+25.3% YoY) and net profit of ₹105.8 Cr (+40.9% YoY) for Q1 FY27.
Jubilant Ingrevia reported highest quarterly revenue and EBITDA in 14 quarters for Q4 FY26, driven by 10% volume growth and specialty chemical momentum.
Jubilant Ingrevia reported record quarterly revenue and EBITDA in Q4FY26, driven by specialty chemicals volume growth and effective handling of Middle East disruptions.
Jubilant Ingrevia Ltd reported revenue from operations of ₹1,179 Cr (+12.1% YoY) and net profit of ₹86.4 Cr (+16.8% YoY) for Q4 FY26.
Revenue flat as strong volume growth offset by persistent pricing pressures across segments. Management maintains optimism based on new CDMO capacity and ESG-driven cost savings.